The dismissal of light, sound, and colour as therapeutic modalities is almost always a categorical error. "That's alternative medicine" is applied to photobiomodulation (which has a documented molecular mechanism in mitochondrial cytochrome c oxidase and hundreds of RCTs) and to singing bowl therapy (which has essentially no published clinical trial evidence) in the same breath, as if they were the same thing.
They are not the same thing. The fact that both involve light or sound does not make them equivalent any more than the fact that both aspirin and tap water involve ingesting a substance makes them equivalent. The question is always the same: what is the mechanism, what is the evidence, and what does the honest risk-benefit calculation look like?
The sunlight baseline — what we are all built to receive
Before assessing therapeutic modalities, it is worth understanding what the full solar spectrum provides to biology: ultraviolet (UV-B) drives vitamin D3 synthesis in skin, with burn risk above therapeutic exposure. Visible blue light (480nm) entrains circadian rhythms via melanopsin-containing retinal ganglion cells (ipRGCs) — the mechanism by which morning light sets the biological clock. Visible red (630–700nm) and near-infrared (700–1100nm) drive photobiomodulation via cytochrome c oxidase in the mitochondrial electron transport chain. Far infrared (>1100nm) produces thermal effects including vasodilation and heat shock protein induction.
Modern indoor life provides artificial visible light (often blue-shifted and lacking the red/NIR component of sunlight) without the UV-B, red, or NIR spectrum components. This is not a minor variation from the ancestral light environment — it is a categorical difference in the electromagnetic information the biology receives.
Light therapies
Mechanism: Circadian entrainment via ipRGC melanopsin receptors → suprachiasmatic nucleus → cortisol/melatonin rhythm normalisation
The most evidence-supported non-pharmacological intervention for Seasonal Affective Disorder (SAD) and a significant body of evidence for non-seasonal depression, circadian rhythm disorders, jet lag, shift work disorder, and dementia-related sleep disturbance. NICE recommends bright light therapy for SAD. Multiple meta-analyses confirm effect sizes comparable to antidepressants in seasonal depression. The mechanism is specific — the blue component of broad-spectrum white light (not UV) activates the ipRGC photoreceptors in the retina that are distinct from the visual photoreceptors and specifically calibrated to detect morning sky blue light for circadian entrainment. 20–30 minutes of 10,000 lux bright light within 30 minutes of waking is the evidence-based protocol.
NICE-recommended for SAD. Meta-analyses show effect size 0.5–0.8 for seasonal depression. Cochrane review supports use in non-seasonal depression as augmentation strategy.
Mechanism: Photon absorption by cytochrome c oxidase (Complex IV of mitochondrial ETC) → increased electron transfer efficiency → elevated ATP production → reduced reactive oxygen species → anti-inflammatory signalling
Photobiomodulation is the application of red (630–700nm) and near-infrared (700–1100nm) light to tissue at non-thermal intensities. The mechanism is documented at the molecular level — cytochrome c oxidase contains copper centres and iron-sulphur clusters that absorb photons in the red/NIR range, accelerating the electron transfer that drives ATP synthesis. This is not an energy medicine hypothesis; it is a documented photochemical reaction in a specific enzyme. The clinical evidence base covers wound healing (multiple RCTs, including FDA-cleared devices), musculoskeletal pain and inflammation (meta-analyses), traumatic brain injury recovery (emerging), and skin health and collagen synthesis. Transcranial PBM for cognitive function in early Alzheimer's is in active clinical trials. The research is significant enough that this is not a fringe modality despite how it is sometimes categorised.
FDA-cleared devices for wound healing and pain. Multiple systematic reviews. Hamblin MR (Harvard) has published extensively on mechanism and clinical applications. Growing evidence for neurological applications via transcranial PBM.
Proposed mechanism: Differential psychological and physiological responses to specific wavelengths of visible light beyond circadian entrainment effects
Chromotherapy — the therapeutic use of specific colours — has a long history in Ayurvedic and traditional medicine. The modern evidence base is thin. There is reasonable evidence for psychological effects of colour on mood and arousal — red environments increase arousal, blue environments are calming in some contexts — but these are mild effects driven primarily by learned associations and contrast rather than specific photobiological mechanisms distinct from what bright light therapy captures. The most honest clinical position: colour environment matters for psychological wellbeing in the sense that the quality of a physical environment affects mood and cognition generally — but the specific colour-as-medicine claims are not supported by clinical evidence at anything close to the standard of bright light or PBM.
Limited RCT evidence. Environmental colour studies show modest psychological effects. Not supported as a primary clinical intervention by current evidence.
Sound therapies
Mechanism: Dopaminergic activation via auditory cortex-limbic connections; autonomic nervous system modulation; cortisol reduction; rhythmic auditory stimulation for motor rehabilitation
Clinical music therapy — delivered by trained music therapists in structured protocols — has the strongest evidence base of any sound-based intervention. In dementia: multiple RCTs demonstrate significant reduction in agitation, improved mood, and maintained autobiographical memory access even in late-stage Alzheimer's. The music-memory connection is specifically preserved later in neurodegeneration than other memory systems — an observation that connects to the distinct hippocampal pathways used for procedural and emotional memory. In palliative care: strong evidence for pain reduction and anxiety management. In psychiatric settings: evidence for depression and anxiety reduction. Neonatal music therapy: evidence for reduced NICU length of stay. Rhythmic Auditory Stimulation (RAS) in stroke rehabilitation: moderate-to-strong evidence for gait improvement via entrainment of motor cortex to musical rhythm.
Cochrane reviews on music therapy in dementia, depression, and palliative care. RAS has growing evidence base for neurological rehabilitation. A distinct and underutilised clinical tool with genuine evidence.
Mechanism: Low-frequency sound vibration (20–100 Hz) transmitted via body contact surfaces → mechanoreceptor stimulation → autonomic modulation; potential vagal afferent activation at specific frequencies
Vibro-acoustic therapy delivers low-frequency sound vibration through surfaces in physical contact with the body — mattresses, chairs, or specialised platforms. The biological mechanisms are plausible: mechanoreceptors throughout the body respond to vibration, and specific frequencies may activate vagal afferents that modulate autonomic tone. There is clinical evidence for pain reduction in fibromyalgia, anxiety reduction, and improvement in Parkinson's tremor. The quality of the evidence is mixed — many studies are small, unblinded, and methodologically limited. The mechanism is distinct from psychological sound response and deserves more rigorous investigation than it has received. Not woo — biologically plausible and promising — but not yet with the evidence base to make strong clinical recommendations.
Small RCTs in fibromyalgia, anxiety, and Parkinson's. Biologically plausible mechanism via mechanoreceptors and potential vagal activation. Warranting larger rigorous trials.
Proposed mechanism: Cortical frequency-following response — when slightly different frequencies are presented to each ear, the brain generates a "beat" at the frequency difference, potentially entraining cortical oscillations toward target frequencies (delta for sleep, theta for relaxation, alpha for focus)
Binaural beats require headphone listening and produce a perceptual beat frequency that differs from both the input frequencies. The cortical entrainment hypothesis is scientifically plausible — EEG studies do show frequency-following responses. Small studies have shown effects on anxiety, relaxation, and sleep onset. The evidence base is inconsistent and often methodologically weak. The honest clinical position: worth trying for individuals who find them useful for relaxation and sleep onset (risk is essentially zero, cost is minimal), but the specific claims about "hacking" brainwave states are ahead of the evidence.
Small studies with inconsistent results. EEG evidence for frequency-following response is real. Clinical benefit evidence is preliminary. Low risk, potentially useful as relaxation aid.
Proposed mechanisms: Relaxation response, potential overlap with VAT at specific frequencies, acoustic resonance effects on autonomic tone
Sound bath experiences using singing bowls, gongs, or other resonant instruments are widely reported as deeply relaxing and subjectively beneficial. The physiological mechanisms are not well characterised. To the extent that the vibration and sound produce genuine autonomic relaxation and parasympathetic activation, the effects are real regardless of the mechanism — the relaxation response has documented physiological benefits including cortisol reduction, heart rate variability improvement, and blood pressure lowering. But the evidence for singing bowl therapy specifically, beyond general relaxation, is very limited. The honest clinical position: if someone finds it beneficial and it promotes a genuine rest-and-digest state, the benefit is real. The specific therapeutic claims beyond relaxation are not evidence-based.
Very limited clinical trial evidence. Subjective benefit reports strong and consistent. Physiological effects likely mediated through relaxation response rather than specific acoustic mechanisms.
The clinical framework for evaluating these modalities
The error in both dismissing and uncritically accepting these modalities is the same: treating them as a category rather than evaluating each on its own mechanism and evidence.
Photobiomodulation via red/NIR light has a specific, documented molecular mechanism — photon absorption by cytochrome c oxidase — and a substantial evidence base. It belongs in a different clinical conversation from general "light healing" claims. Bright light therapy has NICE endorsement and meta-analysis-level evidence. Music therapy in dementia has better evidence than most pharmacological interventions for the same indication.
None of this makes singing bowl therapy evidence-based. But it does mean that a blanket "light and sound therapy is woo" position throws out validated clinical tools alongside speculative ones. The correct clinical position is: evaluate the mechanism, evaluate the evidence, evaluate the risk-benefit ratio, and apply the same critical lens you would to any other intervention.
Photobiomodulation is not in the same category as colour therapy. Music therapy in dementia is not in the same category as crystal healing. The modality is less important than the mechanism and the evidence. Apply the same scrutiny you'd apply to a supplement or a drug.
Interested in what's driving your mitochondrial function?
The OAT maps mitochondrial energy production markers, oxidative stress burden, and the functional context in which photobiomodulation and other regenerative approaches would be most relevant.
Talk to the Concierge
Related reading